Snapshot from Jul 07, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / United Kingdom / GT Biopharma

United Kingdom & GT Biopharma

2 shared events · Importance 3 · Last updated May 27, 2026

Importance
3
Shared Events
2
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
Shared Events (2)
52
Business
SERB_Pharmaceuticals acquires Idefirix rights
United Kingdom: The United Kingdom>>> is one of the regions where SERB Pharmaceuticals>>> will acquire rights to Imlifidase>>>.
GT Biopharma: GT Biopharma>>> divested the European and MENA rights to Imlifidase for 115 million euros, allowing it to focus on other markets and receive significant payments.
May 19, 2026 · 7 articles
42
Business
Splash_Beverage_Group Licenses CannEpil Globally
United Kingdom: United Kingdom is one of the international markets where CannEpil has been authorized for importation and prescription through the Named Patient Request framework.
GT Biopharma: GT Biopharma licensed its CannEpil therapeutic to Splash Beverage Group globally. GT Biopharma will receive a 15% royalty on net revenue from worldwide sales of CannEpil and had approximately $5 million of its indebtedness forgiven by Mercer Street Global Opportunity Fund.
Jul 06, 2026 · 6 articles
NEWSDESK
Explore this relationship live

Track how United Kingdom and GT Biopharma interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.